What Is IGF-1 DES?
A Truncated Form of Insulin-Like Growth Factor 1 Under Study for Growth and Cellular Signaling
IGF-1 DES, also known as Des(1-3) IGF-1, is a shortened form of insulin-like growth factor 1 (IGF-1) in which the first three amino acids of the naturally occurring IGF-1 molecule are absent. Naturally occurring Des(1-3) IGF-1 has been identified in several mammalian tissues and is thought to result from post-translational processing of IGF-1.
It has attracted scientific interest because this structural change substantially reduces its binding to IGF-binding proteins while preserving activity at the IGF-1 receptor. In experimental systems, this can make IGF-1 DES more biologically active than ordinary IGF-1 under certain conditions.
IGF-1 DES is not FDA-approved as a muscle-building, performance, recovery, body-composition, or healthy-aging treatment.
Have questions about peptide therapy? Call Advanced Mobile IV to speak with our team.
What Researchers Are Studying
-
IGF-1 Receptor Signaling
IGF-1 DES retains the ability to interact with the IGF-1 receptor. Researchers use the molecule to study IGF signaling and how interactions with IGF-binding proteins influence the biological activity and availability of growth factors.
-
Cell and Tissue Growth
Experimental research has found that IGF-1 DES can stimulate growth and proliferation in cultured cells and tissues. Its reduced binding to IGF-binding proteins appears to contribute to its greater potency relative to ordinary IGF-1 in some experimental systems.
-
Muscle and Anabolic Signaling
Because the IGF-1 pathway is involved in growth and anabolic physiology, IGF-1 DES has attracted interest in research involving tissue growth and muscle biology. However, experimental activity in these pathways does not establish IGF-1 DES as a proven treatment for increasing muscle mass, strength, or athletic performance.
Quick Answer
IGF-1 DES is not human growth hormone and is not identical to ordinary IGF-1. It is a truncated form of IGF-1 lacking the first three amino acids. Researchers study it because its reduced interaction with IGF-binding proteins can alter its biological activity in experimental systems, but its potential clinical uses have not been established.
At a Glance
What it is
A naturally occurring truncated variant of IGF-1 lacking the first three amino acids at the molecule's N-terminus.
Why it attracts attention
Researchers study IGF-1 DES because it binds much less strongly to IGF-binding proteins while retaining activity at the IGF-1 receptor.
What the evidence looks like
Laboratory and animal research demonstrates significant biological activity, including effects on cell growth and tissue physiology, but clinical applications of IGF-1 DES have not been established.
Important context
Experimental findings involving IGF-1 DES should not be confused with clinical evidence for ordinary IGF-1 or FDA-approved IGF-1 medications.
What We Know - and What Remains Unclear
IGF-1 DES is sometimes discussed in peptide and performance communities as though its greater experimental potency automatically makes it an effective muscle-building, recovery, or performance-enhancing treatment. That interpretation goes beyond the available clinical evidence.
The molecular biology of Des(1-3) IGF-1 has been studied for decades, and its reduced affinity for IGF-binding proteins is well documented. But biological potency in laboratory systems is not the same thing as demonstrated safety or clinical effectiveness in humans. IGF-1 DES should not be presented as an established treatment for muscle growth, strength, athletic performance, recovery, body composition, or healthy aging.
Anyone considering peptide therapy should have an individualized conversation with a qualified provider who can discuss the current evidence, limitations, health history, medications, laboratory information, and growth-factor considerations.
Wellness, Delivered With Care
"Getting IV fluids when I was feeling ill was so beneficial to my healing. I'm grateful for AMIV and the service they provide. I would recommend everyone try this."
Jeff Weaver
Customer
"Very professional. The owners explained this treatment in detail. The procedure I received helped with fatigue and dehydration. I enjoyed the relaxed atmosphere of being in my own home."
Jennifer Belch
Customer
"I have had multiple experiences with Advance Mobile IV and all have been AMAZING! Painless pokes and incredible results, make me feel 100 times better. So thankful I found this company."
Cortlin Beck
Customer
Frequently Asked Questions
Is IGF-1 DES the same as regular IGF-1?
No. IGF-1 DES is a shortened form of IGF-1 that lacks the first three amino acids. This structural difference substantially reduces its binding to IGF-binding proteins.
Why is IGF-1 DES considered more biologically active in some experiments?
Its reduced affinity for IGF-binding proteins can leave more of the molecule available to interact with IGF-1 receptors. In some laboratory systems, this has made IGF-1 DES more potent than ordinary IGF-1.
Has IGF-1 DES been proven to increase muscle mass or athletic performance in humans?
No. Experimental research has demonstrated effects on cellular and tissue growth, but robust human clinical evidence has not established IGF-1 DES as an effective treatment for increasing muscle mass, strength, or athletic performance.
Is IGF-1 DES FDA-approved for muscle growth or recovery?
No. IGF-1 DES is not FDA-approved as a treatment for muscle growth, strength, athletic performance, recovery, body composition, or healthy aging.
Learn More About Peptide Therapy
Peptide science is complicated, particularly when it involves growth factors and cellular signaling. Advanced Mobile IV can help you understand the current conversation around IGF-1 DES and other peptide therapies, the questions to ask, and whether a discussion with a qualified provider makes sense for you.
Call Advanced Mobile IV to Learn MoreThis page is for educational purposes only and is not medical advice. Research and clinical understanding of peptide therapy continue to evolve.
AMIV Wellness Hub
Recent Blog Posts
Mobile IV
Jan 08, 2026
